Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application

Fecha de publicación: 20/09/2024

Autores de IIS La Fe

• Santiago Domingo Del Pozo

  Autor

Participantes ajenos a IIS La Fe

• Casas-Arozamena, Carlos
• Vilar, Ana
• Cueva, Juan
• Arias, Efigenia
• Sampayo, Victoria
• Diaz, Eva
• Oltra, Sara S.
• Moiola, Cristian Pablo
• Cabrera, Silvia
• Cortegoso, Alexandra
• Curiel, Teresa
• Abalo, Alicia
• Serrano, Monica Pamies
• Padilla-Iserte, Pablo
• de la Cruz, Marta Arnaez
• Hernandez, Alicia
• Garcia-Pineda, Virginia
• Ruiz-Banobre, Juan
• Lopez, Rafael
• Matias-Guiu, Xavier
• Colas, Eva
• Gil-Moreno, Antonio
• Abal, Miguel
• Moreno-Bueno, Gema
• Muinelo-Romay, Laura

Grupos

• Grupo de Investigación en tumores ginecológicos, cáncer de mama y cáncer hereditario.

  Investigador Principal

  Víctor Lago Leal

• Medicina Reproductiva

  

  Investigador Principal

  José Morales Roselló

Abstract

Background There has been a rise in endometrial cancer (EC) incidence leading to increased mortality. To counter this trend, improving the stratification of post-surgery recurrence risk and anticipating disease relapse and treatment resistance is essential. Liquid biopsy analyses offer a promising tool for these clinical challenges, though the best strategy for applying them in EC must be defined. This study was designed to determine the value of cfDNA/ctDNA monitoring in improving the clinical management of patients with localized and recurrent disease. Methods Plasma samples and uterine aspirates (UA) from 198 EC patients were collected at surgery and over time. The genetic landscape of UAs was characterized using targeted sequencing. Total cfDNA was analyzed for ctDNA presence based on the UA mutational profile. Results High cfDNA levels and detectable ctDNA at baseline correlated with poor prognosis for DFS (p-value < 0.0001; HR = 9.25) and DSS (p-value < 0.0001; HR = 11.20). This remained clinically significant when stratifying tumors by histopathological risk factors. Of note, cfDNA/ctDNA analyses discriminated patients with early post-surgery relapse and the ctDNA kinetics served to identify patients undergoing relapse before any clinical evidence emerged. Conclusions This is the most comprehensive study on cfDNA/ctDNA characterization in EC, demonstrating its value in improving risk stratification and anticipating disease relapse in patients with localized disease. CtDNA kinetics assessment complements current strategies to monitor the disease evolution and the treatment response. Therefore, implementing cfDNA/ctDNA monitoring in clinical routines offers a unique opportunity to improve EC management. Translational relevance The study demonstrates that high levels of cfDNA and detectable ctDNA at baseline are strong indicators of poor prognosis. This enables more accurate risk stratification beyond traditional histopathological factors, allowing clinicians to identify high-risk patients who may benefit from more aggressive treatment and closer monitoring. Moreover, longitudinal analysis of cfDNA/ctDNA can detect disease recurrence months before clinical symptoms or imaging evidence appear. This early warning system offers a significant advantage in clinical practice, providing a window of opportunity for early intervention and potentially improving patient outcomes.

Keywords

• Liquid Biopsy; Endometrial cancer; Blood biomarkers; Prognostic biomarkers; Tumour kinetics